Key Highlights
● Biodexa received $2.3 million in gross proceeds from a Warrant exercise on September 15, 2026, alongside going-concern warnings.
● By August 19, the Serenta Phase 3 trial had enrolled 87 of a planned 168 subjects across 29 sites.
● BDRX closed at $0.73 on September 18, 2026, down 8.74% on the day, against a 52-week high of $59.40.
● Cash fell to £3.23 million versus £4.61 million of half-year burn, with new funding expected in the fourth quarter.
Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) is a clinical-stage biopharmaceutical company whose American depositary shares trade on Nasdaq. Its recent news flow pairs a pivotal trial that is recruiting well with limited cash to finish it. On September 15, 2026 the company announced a warrant exercise transaction worth $2.3 million in gross proceeds, a deal that sits alongside going-concern language in its regulatory filings.
Pipeline and focus
Biodexa develops treatments for familial adenomatous polyposis, or FAP, non-muscle invasive bladder cancer, type 1 diabetes and aggressive brain cancers. Its lead asset is eRapa, an oral formulation of rapamycin, an mTOR inhibitor, being studied in FAP and in bladder cancer. Tolimidone, a Lyn kinase modulator, is in Phase II development for type 1 diabetes. MTX110, a panobinostat formulation for brain cancers, is described in market data as currently deprioritised. The same data lists MTX240, a molecular glue candidate for gastrointestinal stromal tumours that was in-licensed from Otsuka.
The pivotal programme is the Serenta Phase 3 trial of eRapa in FAP, a randomised, double-blind, placebo-controlled registrational study in high-risk patients planned to enrol 168 participants at sites in the United States and Europe.
Latest announcements and results
On June 29, 2026 the company received Health Canada approval to extend Serenta into Canada. On August 19, 2026 it reported that 87 of a planned 168 subjects had been enrolled across 29 clinical sites, passing the halfway point for recruitment.
On September 11, 2026 it published interim results for the six months ended June 30, 2026. According to a summary of the results, Research and Development costs rose 75% to £2.92 million, the net loss was £1.84 million, operating cash burn increased to £4.61 million and cash fell to £3.23 million. Four days later came the warrant exercise: an investor exercised about 2.2 million ADSs at $1.05 per share, and the company issued new unregistered warrants covering up to 4.4 million additional ADSs.
Share price and capital structure
Market data shows how heavily the shares have been diluted and consolidated. A close of $0.73 was recorded on September 18, 2026, down 8.74% on the day, with a 52-week range of $0.61 to $59.40. The data also lists a one-for-five reverse ADS split announced on March 18, 2026. Separate market data put the close at $1.12 on September 14, 2026 and described the shares as down 96.3% over a year. Market Capitalisation is quoted at roughly $0.75 million to $1.1 million, though share-count figures differ between sources and the values are approximate.
Funding Runway Is the Test for Biodexa's Serenta Trial
The most material risk is funding. Market data shows that recent filings, including a Form 424B3 prospectus supplement, disclose going-concern warnings and say the company expects to require new funding in the fourth quarter of 2026. Cash of £3.23 million against operating cash burn of £4.61 million for the half-year leaves a short runway even after the $2.3 million warrant proceeds. Further Equity raising, with more dilution, is a realistic prospect, though no further raise has been announced.
Other risks are inherent to clinical development: recruitment speed, trial outcomes, regulatory decisions and the minimum bid and equity requirements that apply to Nasdaq-listed companies, although no deficiency notice has been reported. The key markers are Serenta enrolment updates, the next financing announcement, any further capital restructuring, and the full-year results.






Please wait processing your request...